Deciphering the CY 2027 Medicare Advantage & Part D Payment Policies

The Centers for Medicare & Medicaid Services (CMS) released its highly anticipated Calendar Year (CY) 2027 Medicare Advantage (MA) and Part D Rate Announcement. This landmark policy release establishes the financial baseline, actuarial risk adjustment parameters, and regulatory guidelines for Medicare Advantage organizations (MAOs) and prescription drug plan (PDP) sponsors for coverage year 2027.

Deciphering the CY 2027 Medicare Advantage & Part D Payment Policies: A Deep Dive into Rate Updates, Risk Adjustment Reform, and Program Integrity

With an expected net average payment increase of 2.48%—translating to over $13 billion in additional funding flowing into the Medicare Advantage sector—the 2027 announcement represents a delicate balancing act. On one hand, federal regulators seek to maintain market stability and preserve affordable coverage choices for more than 33 million Medicare beneficiaries. On the other hand, CMS is tightening accountability measures by cracking down on aggressive coding practices, phasing out unlinked chart reviews, and aligning Part D risk models with full implementation of the Inflation Reduction Act (IRA).

In this comprehensive analysis, we unpack every major dimension of the CY 2027 final payment policies, exploring what these regulatory changes mean for health plans, risk-bearing provider groups, life sciences companies, and Medicare enrollees.

Executive Summary: Key Highlights at a Glance

Before diving into the operational and actuarial details, here is a high-level summary of the finalized CY 2027 policies:

Net Average Payment Update: A net average rate increase of +2.48% for Medicare Advantage plans, yielding an estimated net increase of over $13 billion in federal payments to MA plans in CY 2027.

Risk Adjustment Model Continuity: CMS will continue utilizing the 2024 CMS-HCC risk adjustment model for CY 2027 while gathering public feedback to guide future iterative updates.

Elimination of Unlinked Chart Reviews: Diagnosis codes derived solely from unlinked chart review records (diagnoses recorded without a corresponding face-to-face service encounter) will be excluded from risk score calculations starting in 2027, subject to a narrow exception for beneficiaries switching MA organizations.

Part D Risk Model Modernization: The Part D risk adjustment model is updated to reflect structural changes under the Inflation Reduction Act (IRA), account for more recent drug costs, and establish distinct risk evaluation methodologies for MA-PD plans versus standalone PDPs.

Strategic Shift in Regulatory Philosophy: Explicit focus on three foundational principles: simplicity in administrative processes, competition based on health plan quality rather than coding intensity, and accuracy in matching payments to true clinical risk.

The Big Picture: Fiscal Context and Leadership Vision

The landscape of Medicare Advantage has expanded dramatically over the past decade. Today, over half of all eligible Medicare beneficiaries are enrolled in private Medicare Advantage plans rather than Original Fee-For-Service (FFS) Medicare. As federal outlays for Medicare Advantage approach nearly $500 billion annually, CMS faces heightened scrutiny from Congress, the Medicare Payment Advisory Commission (MedPAC), and public interest groups regarding payment accuracy and fiscal stewardship.

The 2.48% Net Rate Adjustment Explained

The finalized +2.48% net average change in revenue reflects several intersecting actuarial components:

Effective Growth Rate: Driven by baseline trends in Original Medicare FFS per capita cost growth.

FFS Normalization Factors: Adjustments applied to keep average risk scores across the Medicare population benchmarked over time.

Star Ratings and Quality Bonus Payments (QBPs): Shifts in plan performance ratings that directly affect rebate percentages and benchmark bonuses.

Risk Adjustment Updates: The operational impact of risk model mechanics and diagnostic data filters.

While a 2.48% increase ensures that total federal revenue to MAOs will expand by more than $13 billion in 2027, the effective revenue impact will vary significantly across individual plans based on their geographic service areas, enrollee disease burdens, Star Ratings performance, and historically deployed risk capture tactics.

Strategic Priorities from CMS Leadership

The 2027 Rate Announcement highlights a clear policy shift from CMS leadership, emphasizing program sustainability, coding integrity, and high-value care.

“Medicare Advantage and Part D should work for the people who rely on them. These updates keep coverage affordable and ensure patients get real value from their plans.”

— Dr. Mehmet Oz, CMS Administrator

CMS leadership framed the CY 2027 rate announcement as a vital step toward long-term fiscal solvency while maintaining a robust, competitive marketplace:

“CMS’ vision for Medicare Advantage and Part D is clear: a great choice for seniors and a smart deal for taxpayers. The Rate Announcement improves payment accuracy and strengthens competition based on quality—not on coding practices—helping put the program on a more sustainable path for the long term.”

— Chris Klomp, Director of Medicare and Chief Counselor at HHS

Risk Adjustment Reform: Targeting Coding Intensity & Chart Reviews

The most impactful structural reform in the CY 2027 Rate Announcement centers on risk adjustment integrity. For years, health policy researchers and federal auditors have highlighted a growing divergence between Medicare Advantage risk scores and Original Medicare risk scores—a phenomenon commonly referred to as “coding intensity.”

The Crackdown on Unlinked Chart Review Records

Historically, Medicare Advantage organizations have utilized two primary mechanisms to capture diagnostic data for risk score modeling:

Encounter Data: Diagnoses submitted via direct claims or encounter records tied to specific medical visits, procedures, or treatment sessions.

Chart Reviews: Retrospective reviews of clinical medical records to identify documented conditions that were not captured on original billing claims. These fall into two categories:

Linked Chart Reviews: Diagnoses linked directly to a specific, verifiable beneficiary encounter.

Unlinked Chart Reviews: Diagnoses added to a patient’s profile from clinical documentation without being attached to an underlying encounter or billable service.

The 2027 Final Policy Rule

Beginning in CY 2027, CMS is officially excluding diagnosis information derived from unlinked chart review records from risk score calculations.

Going forward, if a diagnostic code is not tied to a concrete patient encounter, it will not contribute to the enrollee’s Hierarchical Condition Category (HCC) risk score.

[Medical Chart Review Conducted]
│
├── Linked to Specific Encounter? ──────► [INCLUDED in 2027 Risk Score]
│
└── NOT Linked to Specific Encounter? ──► [EXCLUDED in 2027 Risk Score]
(Except Plan Switches)

The Plan-Switching Exception

CMS incorporated a single targeted exception: when a beneficiary transfers from one Medicare Advantage organization to a competing MA plan, the receiving plan may temporarily utilize unlinked chart review diagnoses during the initial transition period. This ensures that new enrollees with complex chronic illnesses do not experience immediate risk-score disruptions simply due to administrative transition lag.

Financial & Operational Impact

This policy change represents a major operational shift for health plan coding operations and vendor ecosystems:

Vendor Reliance Risk: Health plans that have relied heavily on third-party chart review vendors to perform sweeping retrospective record audits without linking diagnoses to care delivery will experience a direct contraction in average risk scores.

Emphasis on Provider Engagement: MAOs must pivot away from retrospective chart scraping toward prospective clinician engagement, ensuring that all documented chronic conditions are actively addressed and coded during documented clinical visits.

Audit and Compliance Refocus: Compliance teams must retool data pipelines to ensure every submitted HCC diagnosis maps cleanly to an encounter control number (ECN) within the CMS Encounter Data System (EDS).

Continuing the 2024 CMS-HCC Risk Adjustment Model

In the CY 2024 Rate Announcement, CMS introduced an overhauled V28 risk model that re-categorized HCCs, removed certain diagnostic codes prone to subjective over-coding, and updated clinical weights using ICD-10 diagnostic mapping. Following a multi-year phase-in completed in CY 2026, CMS confirmed that the 2024 CMS-HCC model will remain fully active for CY 2027.

Rather than introducing a brand-new risk model structure for 2027, CMS opted for stability, granting plans and health systems an opportunity to normalize their clinical documentation under V28 while the agency evaluates ongoing public feedback for future revisions.

CMS’s Three Guiding Principles for Future Risk Adjustment
CMS outlined three core principles that will guide all future iterations of the Medicare Advantage risk adjustment framework:

Principle Strategic Focus & Objective

1. Simplicity: Reduce administrative friction, burden, and operational overhead for both health plans and frontline care providers.
2. Fair Competition: Establish a level playing field where plans compete on clinical care quality, network access, and member experience—rather than financial engineering or specialized coding resources.
3. Accurate Risk Alignment: Ensure federal payments accurately reflect the true health status and resource utilization of enrollees, safeguarding taxpayer funds and preventing artificially inflated growth.
4. Part D Prescription Drug Program Modernization:
   The Medicare Part D program has undergone its most radical transformation since its inception in 2006, driven by the structural provisions of the Inflation Reduction Act (IRA). For CY 2027, CMS is finalizing critical updates to the Part D Risk Adjustment Model to maintain solvency, reflect actual market dynamics, and align prescription drug benefit financing with updated statutory structures.

+———————————————————————–+
| CY 2027 Part D Policy Framework |
+———————————————————————–+
| 1. Full IRA Benefit Codification |
| • $2,000 Out-of-Pocket Cap (Indexed) |
| • Elimination of Coverage Gap (“Donut Hole”) |
| • Manufacturer Discount Program Integration |
+———————————————————————–+
| 2. Market-Segmented Risk Adjustment |
| • Separate Models for MA-PD vs. Standalone PDPs |
+———————————————————————–+
| 3. Cross-Program Diagnostic Data Alignment |
| • Exclusion of Unlinked Chart Reviews across Part C & Part D |
+———————————————————————–+

Key Part D Updates for CY 2027

1. Integration of IRA Benefit Structure
   The CY 2027 Part D risk model fully integrates the revamped benefit design mandated by the IRA:

Annual Out-of-Pocket Cap: Permanent elimination of the traditional “coverage gap” (donut hole) and catastrophic cost-sharing, capping annual enrollee out-of-pocket prescription costs.

Shift in Liability: Health plans now bear a significantly larger share of liability in the catastrophic coverage phase (60% plan liability), replacing the historical 80% federal reinsurance subsidy.

Manufacturer Discount Program: Replaces the former Coverage Gap Discount Program, shifting manufacturer price concessions across broader benefit phases.

2. Segmented Models for MA-PD vs. Standalone PDPs
   Historically, Part D risk adjustment models treated prescription drug risks across MA-PD plans and standalone Prescription Drug Plans (PDPs) under a unified framework. However, underlying utilization profiles, formulary steering mechanisms, and member demographics differ substantially between integrated health plans and standalone drug coverage.

For CY 2027, CMS finalized separate risk calibration models for MA-PD and standalone PDP segments. This separation prevents cross-subsidization, improves bidding accuracy, and helps stabilize the standalone PDP market, which has faced severe margin pressure and contracting plan options in recent years.

3. Diagnostic Source Harmonization
   To maintain consistency across both arms of the Medicare Advantage program, CMS is extending its diagnostic source restrictions to Part D. Diagnosis codes derived from unlinked chart review records will be systematically excluded from Part D risk score calculations, matching the standard established for Part C.
4. Operational & Strategic Impact across the Healthcare Ecosystem
   The finalized 2027 payment policies ripple across every corner of the healthcare industry. Health plan executives, hospital administrators, physician group leaders, and technology vendors must recalibrate their strategic roadmaps. ┌───────────────────────────┐ │ CY 2027 CMS Policies │ └─────────────┬─────────────┘ │ ┌────────────────────────────────┼────────────────────────────────┐ ▼ ▼ ▼ ┌──────────────┐ ┌──────────────┐ ┌──────────────┐
   │ Health Plans │ │ Providers │ │ Beneficiaries│
   ├──────────────┤ ├──────────────┤ ├──────────────┤
   │• $13B+ Growth│ │• Focus on │ │• Premium │
   │• End Unlinked│ │ Face-to-Face│ │ Stability │
   │ Chart Audits│ │ Encounters │ │• Value-Based │
   │• Segmented Part│ │• EHR Workflow│ │ Supplemental│
   │ D Bidding │ │ Integrations│ │ Benefits │
   └──────────────┘ └──────────────┘ └──────────────┘
   Strategic Implications for Medicare Advantage Organizations (MAOs)
   Re-Evaluating Chart Review Vendors: MAOs must immediately audit their third-party risk adjustment contracts. Fee-for-service chart review vendors that focus solely on retrospective chart scraping without encounter-linking capabilities will no longer deliver actionable risk score lift.

Prospective Health Risk Assessments (HRAs): Capital must be redirected toward prospective care gap management, annual wellness visits (AWVs), and in-home health assessments that culminate in a formal, billable clinical encounter.

Actuarial Bidding Precision: With a net rate increase of 2.48%, health plans must exercise rigorous discipline during June bid submissions. Margin assumptions must factor in the loss of unlinked chart review revenue while accounting for rising medical expense ratios (Part C utilization trends) and expanded Part D liability.

Strategic Implications for Health Systems & Risk-Bearing Medical Groups
Integration of Clinical Documentation at the Point of Care: Provider organizations operating under ACO, full-risk capitation, or shared-savings arrangements must ensure that clinical documentation happens dynamically during the patient visit. Electronic Health Record (EHR) tools must prompt clinicians to document and resolve open HCC conditions during active encounters.

Strengthening Encounter Data Pipelines: Risk-bearing medical groups must verify that every claim and encounter file submitted to partner health plans contains complete, compliant ICD-10 diagnostic coding with valid encounter IDs. Failure to transmit complete encounter records risks diagnostic rejection at the CMS level.

Impact on Medicare Beneficiaries

For the nation’s seniors and disabled beneficiaries, the CY 2027 policies provide a combination of stability and protection:

Premium & Coverage Stability: The $13 billion overall increase in federal plan funding helps insulate enrollees from sharp premium spikes or dramatic contractions in core medical benefits.

Protection Against Unnecessary Cost Growth: By reining in coding intensity practices that inflate payments without delivering added clinical care, CMS safeguards the long-term solvency of the Medicare Trust Fund, protecting the program for future generations.

Enhanced Part D Value: Structural Part D risk model adjustments ensure that plans can offer predictable, low-cost access to essential medications under the IRA’s out-of-pocket cap.

5. Comparative Policy Matrix: 2026 vs. 2027
   To visualize the evolution of CMS policy, the following matrix contrasts key policy pillars between CY 2026 and CY 2027:

Policy Area CY 2026 Policy Baseline CY 2027 Finalized Policy Strategic Impact

Net MA Rate Update +5.06% net average rate change (~$25 billion increase) +2.48% net average rate change (~$13 billion increase) Provides revenue growth while reflecting moderating FFS baseline growth dynamics.
Unlinked Chart Reviews: Diagnoses from unlinked chart reviews included in risk score calculations. Excluded from risk score calculations (with plan-switching exception). Eliminates non-encounter diagnostic risk score inflation; shifts focus to prospective encounters.
MA Risk Model Final year of 3-year phase-in of 2024 CMS-HCC V28 model (100% V28). Maintains 100% 2024 CMS-HCC V28 model. Provides operational stability for clinical documentation and risk coding.
Part D Model Calibration: Unified Part D risk model structure; segmented models for MA-PD vs. Standalone PDPs. Improves actuarial precision and bidding stability across distinct Part D markets.
Part D Risk Data Sources: Unlinked chart reviews allowed for Part D risk calculations. Unlinked chart review diagnoses excluded. Harmonizes diagnostic compliance standards across Part C and Part D.
IRA Implementation: Initial rollout of $2,000 out-of-pocket cap and $35 insulin caps. Full codification of IRA benefit redesign and updated risk weights. Aligns plan liability with new out-of-pocket thresholds and manufacturer discount programs.

6. Action Plan for Health Care Executives
   To navigate the transition to the CY 2027 regulatory environment, health plan leadership, compliance officers, and clinical directors should execute a structured, five-step transition plan:

Step 1: Conduct an Unlinked Chart Review Exposure Analysis
Audit historical risk score inputs to quantify the percentage of plan risk scores generated via unlinked chart reviews over the past three payment years. Model the financial impact of removing these diagnoses from 2027 revenue projections.

Step 2: Redesign Vendor Contracts and Incentive Structures
Amend contracts with risk adjustment and clinical documentation vendor partners. Shift performance incentives away from volume-based retrospective chart reviews toward prospective encounter generation, physician education, and point-of-care clinical decision support.

Step 3: Upgrade Encounter Data System (EDS) Data Pipelines
Perform end-to-end testing on Encounter Data System (EDS) submission pipelines. Ensure that every diagnostic code transmitted to CMS maps to an encounter record containing valid clinician identifiers, date-of-service stamps, and billable service codes.

Step 4: Calibrate Part D Actuarial Bidding Assumptions
Actuarial teams must re-estimate Part D bid pricing using the newly segmented MA-PD and PDP risk models. Ensure that formulary designs, manufacturer discount expectations, and catastrophic phase liability assumptions align with finalized IRA parameters.

Step 5: Expand Point-of-Care Provider Enablement
Invest in EHR-integrated clinical workflow tools that present actionable diagnostic gap insights directly to primary care physicians during active patient appointments, converting potential retrospective audits into compliant, prospective clinical encounters.

Will Your Costs Increase or Decrease?

1. High Prescription Drug Spending

• Likely Outcome: Overall Costs Capped (Savings)
• Why: If you take expensive specialty, brand-name, or biologic medications, your overall spending will remain capped. While the out-of-pocket maximum increases slightly from $2,100 in 2026 to $2,400 in 2027, you will still avoid paying thousands of dollars in catastrophic coverage costs compared to pre-2025 rules.

2. Moderate Prescription Drug Spending

• Likely Outcome: Slight Cost Increase
• Why: If you take 1 to 3 brand-name drugs and do not reach the $2,400 out-of-pocket limit, you may experience small increases due to the higher maximum deductible ($700) and potential adjustments to plan copays or drug tiers.

3. Low / Generic Prescription Spending

• Likely Outcome: Mostly Unchanged
• Why: If you rely predominantly on low-cost generic drugs, your out-of-pocket copays are expected to remain low and predictable. However, plan-specific monthly premiums or Tier 1/Tier 2 copays may adjust slightly.

Additional Changes to Watch in 2027

• Changes to Drug Tiers & Formularies: Private Medicare Advantage plans are under pressure to manage overall healthcare costs. They may adjust their formularies (list of covered drugs), move certain medications into higher cost-sharing tiers, or add administrative requirements like prior authorization or step therapy.
• Unlinked Chart Reviews Removed: CMS is excluding diagnostic data from unlinked chart reviews (diagnoses submitted without a corresponding doctor visit encounter) from Medicare Advantage risk scores. While this primarily affects how Medicare pays insurance plans, plans may adjust supplemental benefits or copays to balance their revenue.
• Ending of Temporary Premium Subsidies: The temporary federal Part D Premium Stabilization Demonstration project is winding down, meaning standalone plans and Medicare Advantage plans will recalibrate their standalone prescription pricing to reflect actual costs.

What You Should Do Next

1. Review Your ANOC (Annual Notice of Change): Every September, your Medicare Advantage plan mails an ANOC detailing all changes to premiums, deductibles, copays, and drug formularies for the upcoming year.
2. Check Your Specific Medications: During Medicare Open Enrollment (October 15 – December 7), check whether your specific medications are still on your plan’s formulary and what tier they are assigned to for 2027.

Conclusion: Setting the Stage for Sustainable Healthcare Delivery

The CY 2027 Medicare Advantage and Part D Rate Announcement represents a defining milestone in the modernization of Medicare. By combining a 2.48% rate increase ($13+ billion) with bold structural reforms in risk adjustment, CMS has drawn a clear line in the sand: Medicare Advantage funding must reflect genuine patient encounters, accurate clinical risk, and high-quality care.

By eliminating unlinked chart review records, maintaining the stability of the 2024 CMS-HCC model, and tailoring Part D risk models to modern prescription drug market realities, CMS is steering the program toward long-term sustainability. For healthcare leaders, success in 2027 and beyond will no longer be determined by coding volume, but by the ability to deliver integrated, high-value, encounter-based care that keeps beneficiaries healthy and taxpayer dollars protected.

---